Notch2 is found expressed at about 40% greater levels in patients with advanced stages of NSCLC compared to ones in stage I, and Notch2 overexpression (22% increase) is seen to occur highly significantly in patients with disease recurrence [16]. This evidence concerns the gene NOTCH2 and non-small cell lung carcinoma.